{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T03:14:52Z","timestamp":1788146092150,"version":"build-2803163510"},"reference-count":185,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fibrotic interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), are characterized by an irreversible decline in lung function and high mortality. While two approved antifibrotic therapies, nintedanib and pirfenidone, have been shown to alter the disease trajectory by slowing its progression, the disease remains incurable. This review summarizes current pharmacological treatments for fibrotic interstitial lung disease (f-ILD), mainly IPF and PPF; highlights novel antifibrotic targets such as the lysophosphatidic acid (LPA) receptor; outlines the therapeutic development pipeline; and discusses emerging strategies, including personalized medicine and early intervention.<\/jats:p>","DOI":"10.1515\/mr-2025-0086","type":"journal-article","created":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T17:59:36Z","timestamp":1778435976000},"page":"325-346","source":"Crossref","is-referenced-by-count":0,"title":["Advances in pharmacotherapy for fibrotic interstitial lung disease"],"prefix":"10.1515","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6212-5006","authenticated-orcid":false,"given":"Xiaoguo","family":"Feng","sequence":"first","affiliation":[{"name":"National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine , China-Japan Friendship Hospital , Beijing , China"},{"name":"China-Japan Friendship Hospital, Institute of Clinical Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8978-3309","authenticated-orcid":false,"given":"Mingming","family":"Deng","sequence":"additional","affiliation":[{"name":"National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine , China-Japan Friendship Hospital , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3235-3946","authenticated-orcid":false,"given":"Jinrui","family":"Miao","sequence":"additional","affiliation":[{"name":"National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine , China-Japan Friendship Hospital , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1711-6328","authenticated-orcid":false,"given":"Ziwen","family":"Zheng","sequence":"additional","affiliation":[{"name":"National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine , China-Japan Friendship Hospital , Beijing , China"},{"name":"China-Japan Friendship Hospital, Institute of Clinical Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3438-1764","authenticated-orcid":false,"given":"Gang","family":"Hou","sequence":"additional","affiliation":[{"name":"National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine , China-Japan Friendship Hospital , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"2026083102570599297_j_mr-2025-0086_ref_001","doi-asserted-by":"crossref","unstructured":"Podolanczuk, AJ, Hunninghake, GM, Wilson, KC, Khor, YH, Kheir, F, Pang, B, et al.. Approach to the evaluation and management of interstitial lung abnormalities. An official American thoracic society clinical statement. Am J Respir Crit Care Med 2025;211:1132\u201355. https:\/\/doi.org\/10.1164\/rccm.202505-1054st.","DOI":"10.1164\/rccm.202505-1054ST"},{"key":"2026083102570599297_j_mr-2025-0086_ref_002","doi-asserted-by":"crossref","unstructured":"Katzenstein, ALA, Myers, JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157:1301\u201315. https:\/\/doi.org\/10.1164\/ajrccm.157.4.9707039.","DOI":"10.1164\/ajrccm.157.4.9707039"},{"key":"2026083102570599297_j_mr-2025-0086_ref_003","doi-asserted-by":"crossref","unstructured":"Katzenstein, AL, Fiorelli, RF. Nonspecific interstitial pneumonia\/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 1994;18:136\u201347. https:\/\/doi.org\/10.1097\/00000478-199402000-00003.","DOI":"10.1097\/00000478-199402000-00003"},{"key":"2026083102570599297_j_mr-2025-0086_ref_004","doi-asserted-by":"crossref","unstructured":"Raghu, G, Remy-Jardin, M, Richeldi, L, Thomson, CC, Inoue, Y, Johkoh, T, et al.. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 2022;205:e18\u201347. https:\/\/doi.org\/10.1164\/rccm.202202-0399st.","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2026083102570599297_j_mr-2025-0086_ref_005","doi-asserted-by":"crossref","unstructured":"Althobiani, MA, Russell, AM, Jacob, J, Ranjan, Y, Folarin, AA, Hurst, JR, et al.. Interstitial lung disease: a review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment. Front Med 2024;11:1296890. https:\/\/doi.org\/10.3389\/fmed.2024.1296890.","DOI":"10.3389\/fmed.2024.1296890"},{"key":"2026083102570599297_j_mr-2025-0086_ref_006","doi-asserted-by":"crossref","unstructured":"Zhang, L, Wu, Y, Zhang, J, Qiu, J, Xiao, Y, Chen, Z, et al.. Inequalities and age-period-cohort effects of global and regional burden for interstitial lung disease and pulmonary sarcoidosis: based on global burden of disease study 2021. Front Med 2025;12:1471402. https:\/\/doi.org\/10.3389\/fmed.2025.1471402.","DOI":"10.3389\/fmed.2025.1471402"},{"key":"2026083102570599297_j_mr-2025-0086_ref_007","doi-asserted-by":"crossref","unstructured":"Ma, X, Zhu, L, Kurche, JS, Xiao, H, Dai, H, Wang, C. Global and regional burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2019: results from the global burden of disease study 2019. Thorax 2022;77:596\u2013605. https:\/\/doi.org\/10.1136\/thoraxjnl-2020-216732.","DOI":"10.1136\/thoraxjnl-2020-216732"},{"key":"2026083102570599297_j_mr-2025-0086_ref_008","doi-asserted-by":"crossref","unstructured":"Maher, TM, Bendstrup, E, Dron, L, Langley, J, Smith, G, Khalid, JM, et al.. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res 2021;22:197. https:\/\/doi.org\/10.1186\/s12931-021-01791-z.","DOI":"10.1186\/s12931-021-01791-z"},{"key":"2026083102570599297_j_mr-2025-0086_ref_009","doi-asserted-by":"crossref","unstructured":"Romagnoli, M, Nannini, C, Piciucchi, S, Girelli, F, Gurioli, C, Casoni, G, et al.. Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders? Eur Respir J 2011;38:384\u201391. https:\/\/doi.org\/10.1183\/09031936.00094910.","DOI":"10.1183\/09031936.00094910"},{"key":"2026083102570599297_j_mr-2025-0086_ref_010","doi-asserted-by":"crossref","unstructured":"Raghu, G, Remy-Jardin, M, Ryerson, CJ, Myers, JL, Kreuter, M, Vasakova, M, et al.. Diagnosis of hypersensitivity pneumonitis in adults: an official ATS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 2020;202:e36\u201369. https:\/\/doi.org\/10.1164\/rccm.202005-2032st.","DOI":"10.1164\/rccm.202005-2032ST"},{"key":"2026083102570599297_j_mr-2025-0086_ref_011","doi-asserted-by":"crossref","unstructured":"Kaul, B, Cottin, V, Collard, HR, Valenzuela, C. Variability in global prevalence of interstitial lung disease. Front Med 2021;8:751181. https:\/\/doi.org\/10.3389\/fmed.2021.751181.","DOI":"10.3389\/fmed.2021.751181"},{"key":"2026083102570599297_j_mr-2025-0086_ref_012","doi-asserted-by":"crossref","unstructured":"King, TE, Pardo, A, Selman, M. Idiopathic pulmonary fibrosis. Lancet 2011;378:1949\u201361. https:\/\/doi.org\/10.1016\/s0140-6736(11)60052-4.","DOI":"10.1016\/S0140-6736(11)60052-4"},{"key":"2026083102570599297_j_mr-2025-0086_ref_013","doi-asserted-by":"crossref","unstructured":"Phan, THG, Paliogiannis, P, Nasrallah, GK, Giordo, R, Eid, AH, Fois, AG, et al.. Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis. Cell Mol Life Sci 2021;78:2031\u201357. https:\/\/doi.org\/10.1007\/s00018-020-03693-7.","DOI":"10.1007\/s00018-020-03693-7"},{"key":"2026083102570599297_j_mr-2025-0086_ref_014","doi-asserted-by":"crossref","unstructured":"Inui, N, Sakai, S, Kitagawa, M. Molecular pathogenesis of pulmonary fibrosis, with focus on pathways related to TGF-\u03b2 and the ubiquitin-proteasome pathway. Int J Mol Sci 2021;22:6107. https:\/\/doi.org\/10.3390\/ijms22116107.","DOI":"10.3390\/ijms22116107"},{"key":"2026083102570599297_j_mr-2025-0086_ref_015","doi-asserted-by":"crossref","unstructured":"Lee, CT, Gandhi, SA, Elmrayed, S, Barnes, H, Lorenzetti, D, Salisbury, ML, et al.. Inhalational exposures associated with risk of interstitial lung disease: a systematic review and meta-analysis. Thorax 2025;80:918\u201326. https:\/\/doi.org\/10.1136\/thorax-2024-222306.","DOI":"10.1136\/thorax-2024-222306"},{"key":"2026083102570599297_j_mr-2025-0086_ref_016","doi-asserted-by":"crossref","unstructured":"Shi, M, Zhu, J, Wang, R, Chen, X, Mi, L, Walz, T, et al.. Latent TGF-\u03b2 structure and activation. Nature 2011;474:343\u20139. https:\/\/doi.org\/10.1038\/nature10152.","DOI":"10.1038\/nature10152"},{"key":"2026083102570599297_j_mr-2025-0086_ref_017","doi-asserted-by":"crossref","unstructured":"Annes, JP, Munger, JS, Rifkin, DB. Making sense of latent TGF\u03b2 activation. J\u00a0Cell Sci 2003;116:217\u201324. https:\/\/doi.org\/10.1242\/jcs.00229.","DOI":"10.1242\/jcs.00229"},{"key":"2026083102570599297_j_mr-2025-0086_ref_018","doi-asserted-by":"crossref","unstructured":"Hu, HH, Chen, DQ, Wang, YN, Feng, YL, Cao, G, Vaziri, ND, et al.. New insights into TGF-\u03b2\/smad signaling in tissue fibrosis. Chem Biol Interact 2018;292:76\u201383. https:\/\/doi.org\/10.1016\/j.cbi.2018.07.008.","DOI":"10.1016\/j.cbi.2018.07.008"},{"key":"2026083102570599297_j_mr-2025-0086_ref_019","doi-asserted-by":"crossref","unstructured":"Sheikh, K, Amjad, M, Irfan, M, Anjum, S, Majeed, T, Riaz, M, et al.. Exploring TGF-\u03b2 signaling in cancer progression: prospects and therapeutic strategies. OncoTargets Ther 2025;18:233\u201362. https:\/\/doi.org\/10.2147\/ott.s493643.","DOI":"10.2147\/OTT.S493643"},{"key":"2026083102570599297_j_mr-2025-0086_ref_020","doi-asserted-by":"crossref","unstructured":"Dolivo, D, Larson, S, Dominko, T. Crosstalk between mitogen-activated protein kinase inhibitors and transforming growth factor-\u03b2 signaling results in variable activation of human dermal fibroblasts. Int J Mol Med 2018;43:325\u201335. https:\/\/doi.org\/10.3892\/ijmm.2018.3949.","DOI":"10.3892\/ijmm.2018.3949"},{"key":"2026083102570599297_j_mr-2025-0086_ref_021","doi-asserted-by":"crossref","unstructured":"Han, H, Li, M, Liu, H, Li, H. Electroacupuncture regulates inflammation, collagen deposition and macrophage function in skeletal muscle through the TGF-\u03b21\/Smad3\/p38\/ERK1\/2 pathway. Exp Ther Med 2021;22:1457. https:\/\/doi.org\/10.3892\/etm.2021.10892.","DOI":"10.3892\/etm.2021.10892"},{"key":"2026083102570599297_j_mr-2025-0086_ref_022","doi-asserted-by":"crossref","unstructured":"Nakazawa, S, Hou, J, Kato, M, Togo, S, Arai, Y, Motomura, H, et al.. Allicin induced AMPK signaling attenuated Smad3 pathway mediated lung fibrosis. Sci Rep 2025;15:19060. https:\/\/doi.org\/10.1038\/s41598-025-01314-6.","DOI":"10.1038\/s41598-025-01314-6"},{"key":"2026083102570599297_j_mr-2025-0086_ref_023","doi-asserted-by":"crossref","unstructured":"Shi, L, Wang, Z, Rong, J, Fei, X, Li, X, He, B, et al.. Inhibition of TGF-\u03b21-induced epithelial-mesenchymal transition in gliomas by DMC-HA. Aging (Milano) 2023;15:15183\u201395. https:\/\/doi.org\/10.18632\/aging.205340.","DOI":"10.18632\/aging.205340"},{"key":"2026083102570599297_j_mr-2025-0086_ref_024","doi-asserted-by":"crossref","unstructured":"Maseki, S, Ijichi, K, Tanaka, H, Fujii, M, Hasegawa, Y, Ogawa, T, et al.. Acquisition of EMT phenotype in the gefitinib-resistant cells of a\u00a0head and neck squamous cell carcinoma cell line through akt\/GSK-3\u03b2\/snail signalling pathway. Br J Cancer 2012;106:1196\u2013204. https:\/\/doi.org\/10.1038\/bjc.2012.24.","DOI":"10.1038\/bjc.2012.24"},{"key":"2026083102570599297_j_mr-2025-0086_ref_025","doi-asserted-by":"crossref","unstructured":"Peng, D, Fu, M, Wang, M, Wei, Y, Wei, X. Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy. Mol Cancer 2022;21:104. https:\/\/doi.org\/10.1186\/s12943-022-01569-x.","DOI":"10.1186\/s12943-022-01569-x"},{"key":"2026083102570599297_j_mr-2025-0086_ref_026","doi-asserted-by":"crossref","unstructured":"Ying, HZ, Chen, Q, Zhang, WY, Zhang, HH, Ma, Y, Zhang, SZ, et al.. PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics. Mol Med Rep 2017;16:7879\u201389. https:\/\/doi.org\/10.3892\/mmr.2017.7641.","DOI":"10.3892\/mmr.2017.7641"},{"key":"2026083102570599297_j_mr-2025-0086_ref_027","doi-asserted-by":"crossref","unstructured":"Rupp, E, Siegbahn, A, R\u00f6nnstrand, L, Wernstedt, C, Claesson\u2010Welsh, L, Heldin, C. A unique autophosphorylation site in the platelet\u2010derived growth factor \u03b1 receptor from a heterodimeric receptor complex. Eur J Biochem 1994;225:29\u201341. https:\/\/doi.org\/10.1111\/j.1432-1033.1994.00029.x.","DOI":"10.1111\/j.1432-1033.1994.00029.x"},{"key":"2026083102570599297_j_mr-2025-0086_ref_028","doi-asserted-by":"crossref","unstructured":"W\u00e5hl\u00e9n, E, Olsson, F, Raykova, D, S\u00f6derberg, O, Heldin, J, Lennartsson, J. Activated EGFR and PDGFR internalize in separate vesicles and downstream AKT and ERK1\/2 signaling are differentially impacted by cholesterol depletion. Biochem Biophys Res Commun 2023;665:195\u2013201. https:\/\/doi.org\/10.1016\/j.bbrc.2023.04.099.","DOI":"10.1016\/j.bbrc.2023.04.099"},{"key":"2026083102570599297_j_mr-2025-0086_ref_029","doi-asserted-by":"crossref","unstructured":"Kishi, M, Aono, Y, Sato, S, Koyama, K, Azuma, M, Abe, S, et al.. Blockade of platelet-derived growth factor receptor-\u03b2, not receptor-\u03b1 ameliorates bleomycin-induced pulmonary fibrosis in mice. PLoS One 2018;13:e0209786. https:\/\/doi.org\/10.1371\/journal.pone.0209786.","DOI":"10.1371\/journal.pone.0209786"},{"key":"2026083102570599297_j_mr-2025-0086_ref_030","doi-asserted-by":"crossref","unstructured":"Pan, L, Cheng, Y, Yang, W, Wu, X, Zhu, H, Hu, M, et al.. Nintedanib ameliorates bleomycin-induced pulmonary fibrosis, inflammation, apoptosis, and oxidative stress by modulating PI3K\/akt\/mTOR pathway in mice. Inflammation 2023;46:1531\u201342. https:\/\/doi.org\/10.1007\/s10753-023-01825-2.","DOI":"10.1007\/s10753-023-01825-2"},{"key":"2026083102570599297_j_mr-2025-0086_ref_031","doi-asserted-by":"crossref","unstructured":"Gong, Y, Hu, Y, Huang, J, Wang, H. RAB11A aggravates PDGF-BB-stimulated proliferation, migration, and inflammation of airway smooth muscle cells via affecting the NF-\u03baB and PI3K\/AKT pathways. Allergol Immunopathol 2022;50:147\u201354. https:\/\/doi.org\/10.15586\/aei.v50i4.635.","DOI":"10.15586\/aei.v50i4.635"},{"key":"2026083102570599297_j_mr-2025-0086_ref_032","doi-asserted-by":"crossref","unstructured":"Reyhani, V, Tsioumpekou, M, Van Wieringen, T, Rask, L, Lennartsson, J, Rubin, K. PDGF-BB enhances collagen gel contraction through a PI3K-PLC\u03b3-PKC-cofilin pathway. Sci Rep 2017;7:8924. https:\/\/doi.org\/10.1038\/s41598-017-08411-1.","DOI":"10.1038\/s41598-017-08411-1"},{"key":"2026083102570599297_j_mr-2025-0086_ref_033","doi-asserted-by":"crossref","unstructured":"Zeng, G, Cui, X, Liu, Z, Zhao, H, Zheng, X, Zhang, B, et al.. Disruption of phosphoinositide-specific phospholipases C\u03b31 contributes to extracellular matrix synthesis of human osteoarthritis chondrocytes. IJMS 2014;15:13236\u201346. https:\/\/doi.org\/10.3390\/ijms150813236.","DOI":"10.3390\/ijms150813236"},{"key":"2026083102570599297_j_mr-2025-0086_ref_034","doi-asserted-by":"crossref","unstructured":"Elkiki, SM, Mansour, HH, Anis, LM, Gabr, HM, Kamal, MM. Evaluation of aromatase inhibitor on radiation induced pulmonary fibrosis via TGF- \u03b2\/smad 3 and TGF- \u03b2\/PDGF pathways in rats. Toxicol Mech Methods 2021;31:538\u201345. https:\/\/doi.org\/10.1080\/15376516.2021.1934765.","DOI":"10.1080\/15376516.2021.1934765"},{"key":"2026083102570599297_j_mr-2025-0086_ref_035","doi-asserted-by":"crossref","unstructured":"Parimon, T, Yao, C, Stripp, BR, Noble, PW, Chen, P. Alveolar epithelial type II cells as drivers of lung fibrosis in idiopathic pulmonary fibrosis. Int J Mol Sci 2020;21:2269. https:\/\/doi.org\/10.3390\/ijms21072269.","DOI":"10.3390\/ijms21072269"},{"key":"2026083102570599297_j_mr-2025-0086_ref_036","doi-asserted-by":"crossref","unstructured":"Selman, M, Pardo, A. When things go wrong: exploring possible mechanisms driving the progressive fibrosis phenotype in interstitial lung diseases. Eur Respir J 2021;58:2004507. https:\/\/doi.org\/10.1183\/13993003.04507-2020.","DOI":"10.1183\/13993003.04507-2020"},{"key":"2026083102570599297_j_mr-2025-0086_ref_037","doi-asserted-by":"crossref","unstructured":"Gao, DK, Salomonis, N, Henderlight, M, Woods, C, Thakkar, K, Grom, AA, et al.. IFN-\u03b3 is essential for alveolar macrophage\u2013driven pulmonary inflammation in macrophage activation syndrome. JCI Insight 2021;6:e147593. https:\/\/doi.org\/10.1172\/jci.insight.147593.","DOI":"10.1172\/jci.insight.147593"},{"key":"2026083102570599297_j_mr-2025-0086_ref_038","doi-asserted-by":"crossref","unstructured":"Xu, Y, Lan, P, Wang, T. The role of immune cells in the pathogenesis of idiopathic pulmonary fibrosis. Medicina (Mex) 2023;59:1984. https:\/\/doi.org\/10.3390\/medicina59111984.","DOI":"10.3390\/medicina59111984"},{"key":"2026083102570599297_j_mr-2025-0086_ref_039","doi-asserted-by":"crossref","unstructured":"Ouyang, S, Liu, C, Xiao, J, Chen, X, Lui, AC, Li, X. Targeting IL-17A\/glucocorticoid synergy to CSF3 expression in neutrophilic airway diseases. JCI Insight 2020;5:e132836. https:\/\/doi.org\/10.1172\/jci.insight.132836.","DOI":"10.1172\/jci.insight.132836"},{"key":"2026083102570599297_j_mr-2025-0086_ref_040","doi-asserted-by":"crossref","unstructured":"Roos, AB, Sethi, S, Nikota, J, Wrona, CT, Dorrington, MG, Sand\u00e9n, C, et al.. IL-17A and the promotion of neutrophilia in acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192:428\u201337. https:\/\/doi.org\/10.1164\/rccm.201409-1689oc.","DOI":"10.1164\/rccm.201409-1689OC"},{"key":"2026083102570599297_j_mr-2025-0086_ref_041","doi-asserted-by":"crossref","unstructured":"Asker, ME, Abdelmeged, AA, Shaheen, MA, Eissa, RG. Sunitinib displays pulmonary fibrosis in experimental rats: role of IL-17A dependent pathway. Int Immunopharmacol 2023;119:110173. https:\/\/doi.org\/10.1016\/j.intimp.2023.110173.","DOI":"10.1016\/j.intimp.2023.110173"},{"key":"2026083102570599297_j_mr-2025-0086_ref_042","doi-asserted-by":"crossref","unstructured":"Cipolla, E, Fisher, AJ, Gu, H, Mickler, EA, Agarwal, M, Wilke, CA, et al.. IL\u201017A deficiency mitigates bleomycin\u2010induced complement activation during lung fibrosis. FASEB J 2017;31:5543\u201356. https:\/\/doi.org\/10.1096\/fj.201700289r.","DOI":"10.1096\/fj.201700289R"},{"key":"2026083102570599297_j_mr-2025-0086_ref_043","doi-asserted-by":"crossref","unstructured":"Zhang, J, Wang, D, Wang, L, Wang, S, Roden, AC, Zhao, H, et al.. Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A\/IL-17RA in human fibrotic interstitial lung disease. Am J Physiol Lung Cell Mol Physiol 2019;316:L487\u201397. https:\/\/doi.org\/10.1152\/ajplung.00301.2018.","DOI":"10.1152\/ajplung.00301.2018"},{"key":"2026083102570599297_j_mr-2025-0086_ref_044","doi-asserted-by":"crossref","unstructured":"Ng, B, Dong, J, D\u2019Agostino, G, Viswanathan, S, Widjaja, AA, Lim, WW, et al.. Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis. Sci Transl Med 2019;11:eaaw1237. https:\/\/doi.org\/10.1126\/scitranslmed.aaw1237.","DOI":"10.1126\/scitranslmed.aaw1237"},{"key":"2026083102570599297_j_mr-2025-0086_ref_045","doi-asserted-by":"crossref","unstructured":"Ng, B, Cook, SA, Schafer, S. Interleukin-11 signaling underlies fibrosis, parenchymal dysfunction, and chronic inflammation of the airway. Exp Mol Med 2020;52:1871\u20138. https:\/\/doi.org\/10.1038\/s12276-020-00531-5.","DOI":"10.1038\/s12276-020-00531-5"},{"key":"2026083102570599297_j_mr-2025-0086_ref_046","doi-asserted-by":"crossref","unstructured":"Byrne, AJ, Maher, TM, Lloyd, CM. Pulmonary macrophages: a new therapeutic pathway in fibrosing lung disease? Trends Mol Med 2016;22:303\u201316. https:\/\/doi.org\/10.1016\/j.molmed.2016.02.004.","DOI":"10.1016\/j.molmed.2016.02.004"},{"key":"2026083102570599297_j_mr-2025-0086_ref_047","doi-asserted-by":"crossref","unstructured":"Wang, Y, Zhang, L, Wu, GR, Zhou, Q, Yue, H, Rao, LZ, et al.. MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program. Sci Adv 2021;7:eabb6075. https:\/\/doi.org\/10.1126\/sciadv.abb6075.","DOI":"10.1126\/sciadv.abb6075"},{"key":"2026083102570599297_j_mr-2025-0086_ref_048","doi-asserted-by":"crossref","unstructured":"Li, Q, Cheng, Y, Zhang, Z, Bi, Z, Ma, X, Wei, Y, et al.. Inhibition of ROCK ameliorates pulmonary fibrosis by suppressing M2 macrophage polarisation through phosphorylation of STAT3. Clin Transl Med 2022;12:e1036. https:\/\/doi.org\/10.1002\/ctm2.1036.","DOI":"10.1002\/ctm2.1036"},{"key":"2026083102570599297_j_mr-2025-0086_ref_049","doi-asserted-by":"crossref","unstructured":"Borie, R, Kannengiesser, C, Nathan, N, Tab\u00e8ze, L, Prad\u00e8re, P, Crestani, B. Familial pulmonary fibrosis. Rev Mal Respir 2015;32:413\u201334. https:\/\/doi.org\/10.1016\/j.rmr.2014.07.017.","DOI":"10.1016\/j.rmr.2014.07.017"},{"key":"2026083102570599297_j_mr-2025-0086_ref_050","doi-asserted-by":"crossref","unstructured":"Tirelli, C, Pesenti, C, Miozzo, M, Mondoni, M, Fontana, L, Centanni, S. The genetic and epigenetic footprint in idiopathic pulmonary fibrosis and familial pulmonary fibrosis: a state-of-the-art review. Diagnostics 2022;12:3107. https:\/\/doi.org\/10.3390\/diagnostics12123107.","DOI":"10.3390\/diagnostics12123107"},{"key":"2026083102570599297_j_mr-2025-0086_ref_051","doi-asserted-by":"crossref","unstructured":"Borie, R, Kannengiesser, C, Antoniou, K, Bonella, F, Crestani, B, Fabre, A, et al.. European respiratory society statement on familial pulmonary fibrosis. Eur Respir J 2023;61:2201383. https:\/\/doi.org\/10.1183\/13993003.01383-2022.","DOI":"10.1183\/13993003.01383-2022"},{"key":"2026083102570599297_j_mr-2025-0086_ref_052","doi-asserted-by":"crossref","unstructured":"Stock, CJ, Conti, C, Montero-Fernandez, \u00c1, Caramori, G, Molyneaux, PL, George, PM, et al.. Interaction between the promoter MUC5B polymorphism and mucin expression: is there a difference according to ILD subtype? Thorax 2020;75:901\u20133. https:\/\/doi.org\/10.1136\/thoraxjnl-2020-214579.","DOI":"10.1136\/thoraxjnl-2020-214579"},{"key":"2026083102570599297_j_mr-2025-0086_ref_053","doi-asserted-by":"crossref","unstructured":"Hunninghake, GM, Hatabu, H, Okajima, Y, Gao, W, Dupuis, J, Latourelle, JC, et al.. MUC5B promoter polymorphism and interstitial lung abnormalities. N\u00a0Engl J Med 2013;368:2192\u2013200. https:\/\/doi.org\/10.1056\/nejmoa1216076.","DOI":"10.1056\/NEJMoa1216076"},{"key":"2026083102570599297_j_mr-2025-0086_ref_054","doi-asserted-by":"crossref","unstructured":"Katzenstein, ALA. Smoking-related interstitial fibrosis (SRIF), pathogenesis and treatment of usual interstitial pneumonia (UIP),\u00a0and transbronchial biopsy in UIP. Mod Pathol 2012;25:S68\u201378. https:\/\/doi.org\/10.1038\/modpathol.2011.154.","DOI":"10.1038\/modpathol.2011.154"},{"key":"2026083102570599297_j_mr-2025-0086_ref_055","doi-asserted-by":"crossref","unstructured":"Kanaji, N, Basma, H, Nelson, A, Farid, M, Sato, T, Nakanishi, M, et al.. Fibroblasts that resist cigarette smoke-induced senescence acquire profibrotic phenotypes. Am J Physiol Lung Cell Mol Physiol 2014;307:L364\u201373. https:\/\/doi.org\/10.1152\/ajplung.00041.2014.","DOI":"10.1152\/ajplung.00041.2014"},{"key":"2026083102570599297_j_mr-2025-0086_ref_056","doi-asserted-by":"crossref","unstructured":"Prasad, P, Sriram, G, Kannan, B, Jaber, M, Khair, AMB, Ramasubramanian, A, et al.. Waterpipe smoke condensate activates the oncogenes and promotes epithelial\u2013mesenchymal transition to cause oral cancer. Odontology 2025;114:339\u201348. https:\/\/doi.org\/10.1007\/s10266-025-01127-z.","DOI":"10.1007\/s10266-025-01127-z"},{"key":"2026083102570599297_j_mr-2025-0086_ref_057","doi-asserted-by":"crossref","unstructured":"Wollin, L, Wex, E, Pautsch, A, Schnapp, G, Hostettler, KE, Stowasser, S, et al.. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1434\u201345. https:\/\/doi.org\/10.1183\/09031936.00174914.","DOI":"10.1183\/09031936.00174914"},{"key":"2026083102570599297_j_mr-2025-0086_ref_058","doi-asserted-by":"crossref","unstructured":"Richeldi, L, Du Bois, RM, Raghu, G, Azuma, A, Brown, KK, Costabel, U, et al.. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N\u00a0Engl J Med 2014;370:2071\u201382. https:\/\/doi.org\/10.1056\/nejmoa1402584.","DOI":"10.1056\/NEJMoa1402584"},{"key":"2026083102570599297_j_mr-2025-0086_ref_059","doi-asserted-by":"crossref","unstructured":"McCormack, PL. Nintedanib: first global approval. Drugs 2015;75:129\u201339. https:\/\/doi.org\/10.1007\/s40265-014-0335-0.","DOI":"10.1007\/s40265-014-0335-0"},{"key":"2026083102570599297_j_mr-2025-0086_ref_060","doi-asserted-by":"crossref","unstructured":"Flaherty, KR, Wells, AU, Cottin, V, Devaraj, A, Walsh, SLF, Inoue, Y, et al.. Nintedanib in progressive fibrosing interstitial lung diseases. N\u00a0Engl J Med 2019;381:1718\u201327. https:\/\/doi.org\/10.1056\/nejmoa1908681.","DOI":"10.1056\/NEJMoa1908681"},{"key":"2026083102570599297_j_mr-2025-0086_ref_061","doi-asserted-by":"crossref","unstructured":"Raghu, G, Montesi, SB, Silver, RM, Hossain, T, Macrea, M, Herman, D, et al.. Treatment of systemic sclerosis\u2013associated interstitial lung disease: evidence-based recommendations. An official American thoracic society clinical practice guideline. Am J Respir Crit Care Med 2024;209:137\u201352. https:\/\/doi.org\/10.1164\/rccm.202306-1113st.","DOI":"10.1164\/rccm.202306-1113ST"},{"key":"2026083102570599297_j_mr-2025-0086_ref_062","doi-asserted-by":"crossref","unstructured":"Highland, KB, Distler, O, Kuwana, M, Allanore, Y, Assassi, S, Azuma, A, et al.. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med 2021;9:96\u2013106. https:\/\/doi.org\/10.1016\/s2213-2600(20)30330-1.","DOI":"10.1016\/S2213-2600(20)30330-1"},{"key":"2026083102570599297_j_mr-2025-0086_ref_063","doi-asserted-by":"crossref","unstructured":"Yang, M, Tan, Y, Yang, T, Xu, D, Chen, M, Chen, L. Efficacy and safety of antifibrotic drugs for interstitial lung diseases other than IPF: a systematic review, meta-analysis and trial sequential analysis. PLoS One 2025;20:e0318877. https:\/\/doi.org\/10.1371\/journal.pone.0318877.","DOI":"10.1371\/journal.pone.0318877"},{"key":"2026083102570599297_j_mr-2025-0086_ref_064","doi-asserted-by":"crossref","unstructured":"Richeldi, L, Cottin, V, Du Bois, RM, Selman, M, Kimura, T, Bailes, Z, et al.. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS\u00ae trials. Respir Med 2016;113:74\u20139. https:\/\/doi.org\/10.1016\/j.rmed.2016.02.001.","DOI":"10.1016\/j.rmed.2016.02.001"},{"key":"2026083102570599297_j_mr-2025-0086_ref_065","doi-asserted-by":"crossref","unstructured":"Wind, S, Schmid, U, Freiwald, M, Marzin, K, Lotz, R, Ebner, T, et al.. Clinical pharmacokinetics and pharmacodynamics of nintedanib. Clin Pharmacokinet 2019;58:1131\u201347. https:\/\/doi.org\/10.1007\/s40262-019-00766-0.","DOI":"10.1007\/s40262-019-00766-0"},{"key":"2026083102570599297_j_mr-2025-0086_ref_066","doi-asserted-by":"crossref","unstructured":"Chen, Z, Yang, J, Zhang, Q, Zeng, W, Liu, Y, Hu, W, et al.. Inhalable myofibroblast targeting nanoparticles for synergistic treatment of pulmonary fibrosis. Sci Adv 2025;11:eadv9571. https:\/\/doi.org\/10.1126\/sciadv.adv9571.","DOI":"10.1126\/sciadv.adv9571"},{"key":"2026083102570599297_j_mr-2025-0086_ref_067","doi-asserted-by":"crossref","unstructured":"Potts, J, Yogaratnam, D. Pirfenidone: a novel agent for the treatment of idiopathic pulmonary fibrosis. Ann Pharmacother 2013;47:361\u20137. https:\/\/doi.org\/10.1345\/aph.1r337.","DOI":"10.1345\/aph.1R337"},{"key":"2026083102570599297_j_mr-2025-0086_ref_068","doi-asserted-by":"crossref","unstructured":"Ying, H, Fang, M, Hang, QQ, Chen, Y, Qian, X, Chen, M. Pirfenidone modulates macrophage polarization and ameliorates radiation\u2010induced lung fibrosis by inhibiting the TGF\u2010\u03b21\/Smad3 pathway. J\u00a0Cell Mol Med 2021;25:8662\u201375. https:\/\/doi.org\/10.1111\/jcmm.16821.","DOI":"10.1111\/jcmm.16821"},{"key":"2026083102570599297_j_mr-2025-0086_ref_069","doi-asserted-by":"crossref","unstructured":"Lv, Q, Wang, J, Xu, C, Huang, X, Ruan, Z, Dai, Y. Pirfenidone alleviates pulmonary fibrosis in\u00a0vitro and in\u00a0vivo through regulating wnt\/GSK-3\u03b2\/\u03b2-catenin and TGF-\u03b21\/Smad2\/3 signaling pathways. Mol Med 2020;26:49. https:\/\/doi.org\/10.1186\/s10020-020-00173-3.","DOI":"10.1186\/s10020-020-00173-3"},{"key":"2026083102570599297_j_mr-2025-0086_ref_070","doi-asserted-by":"crossref","unstructured":"Tang, Q, Xing, C, Li, M, Jia, Q, Bo, C, Zhang, Z. Pirfenidone ameliorates pulmonary inflammation and fibrosis in a rat silicosis model by inhibiting macrophage polarization and JAK2\/STAT3 signaling pathways. Ecotoxicol Environ Saf 2022;244:114066. https:\/\/doi.org\/10.1016\/j.ecoenv.2022.114066.","DOI":"10.1016\/j.ecoenv.2022.114066"},{"key":"2026083102570599297_j_mr-2025-0086_ref_071","doi-asserted-by":"crossref","unstructured":"Noble, PW, Albera, C, Bradford, WZ, Costabel, U, Glassberg, MK, Kardatzke, D, et al.. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377:1760\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(11)60405-4.","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2026083102570599297_j_mr-2025-0086_ref_072","doi-asserted-by":"crossref","unstructured":"King, TE, Bradford, WZ, Castro-Bernardini, S, Fagan, EA, Glaspole, I, Glassberg, MK, et al.. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N\u00a0Engl J Med 2014;370:2083\u201392. https:\/\/doi.org\/10.1056\/nejmoa1402582.","DOI":"10.1056\/NEJMoa1402582"},{"key":"2026083102570599297_j_mr-2025-0086_ref_073","doi-asserted-by":"crossref","unstructured":"Wang, P, Li, H, Chen, S, Xing, H, Yang, J, Zhang, G, et al.. Multicenter population pharmacokinetics and exposure\u2013efficacy analysis of pirfenidone in patients with idiopathic pulmonary fibrosis. Clin Pharmacokinet 2023;62:921\u201330. https:\/\/doi.org\/10.1007\/s40262-023-01250-6.","DOI":"10.1007\/s40262-023-01250-6"},{"key":"2026083102570599297_j_mr-2025-0086_ref_074","doi-asserted-by":"crossref","unstructured":"Behr, J, Prasse, A, Kreuter, M, Johow, J, Rabe, KF, Bonella, F, et al.. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021;9:476\u201386. https:\/\/doi.org\/10.1016\/s2213-2600(20)30554-3.","DOI":"10.1016\/S2213-2600(20)30554-3"},{"key":"2026083102570599297_j_mr-2025-0086_ref_075","doi-asserted-by":"crossref","unstructured":"Maher, TM, Corte, TJ, Fischer, A, Kreuter, M, Lederer, DJ, Molina-Molina, M, et al.. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2020;8:147\u201357. https:\/\/doi.org\/10.1016\/s2213-2600(19)30341-8.","DOI":"10.1016\/S2213-2600(19)30341-8"},{"key":"2026083102570599297_j_mr-2025-0086_ref_076","doi-asserted-by":"crossref","unstructured":"Yoon, HY, Kim, H, Bae, Y, Song, JW. Pirfenidone and risk of lung cancer development in idiopathic pulmonary fibrosis: a nationwide population-based study. Eur Respir J 2025;65:2401484. https:\/\/doi.org\/10.1183\/13993003.01484-2024.","DOI":"10.1183\/13993003.01484-2024"},{"key":"2026083102570599297_j_mr-2025-0086_ref_077","doi-asserted-by":"crossref","unstructured":"Morgado\u2010Carrasco, D, Massana, J, Piquero\u2010Casals, J. Pirfenidone\u2010induced phototoxic reaction. Int J Dermatol 2021;60:e202\u20133. https:\/\/doi.org\/10.1111\/ijd.15361.","DOI":"10.1111\/ijd.15361"},{"key":"2026083102570599297_j_mr-2025-0086_ref_078","doi-asserted-by":"crossref","unstructured":"Dwivedi, N, Witherspoon, J, Yong\u2010Gee, S. Pirfenidone\u2010induced photolichenoid drug eruption. Australas J Dermatol 2023;64:299\u2013301. https:\/\/doi.org\/10.1111\/ajd.14010.","DOI":"10.1111\/ajd.14010"},{"key":"2026083102570599297_j_mr-2025-0086_ref_079","doi-asserted-by":"crossref","unstructured":"Kang, Jhyun, Yoo, SD, Han, KH, Jeong, SJ, Lee, HJ, Yoo, JH, et al.. Characterization of channeling effects applied to extended-release matrix tablets containing pirfenidone. Chem Pharm Bull 2023;71:678\u201386. https:\/\/doi.org\/10.1248\/cpb.c23-00216.","DOI":"10.1248\/cpb.c23-00216"},{"key":"2026083102570599297_j_mr-2025-0086_ref_080","doi-asserted-by":"crossref","unstructured":"Kang, JH, Yang, MS, Kim, DW, Park, CW. In vivo pharmacokinetic and pharmacodynamic study of co-spray-dried inhalable pirfenidone microparticles in rats. Drug Deliv 2022;29:3384\u201396. https:\/\/doi.org\/10.1080\/10717544.2022.2149899.","DOI":"10.1080\/10717544.2022.2149899"},{"key":"2026083102570599297_j_mr-2025-0086_ref_081","doi-asserted-by":"crossref","unstructured":"Kolb, M, Crestani, B, Maher, TM. Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis. Eur Respir Rev 2023;32:220206. https:\/\/doi.org\/10.1183\/16000617.0206-2022.","DOI":"10.1183\/16000617.0206-2022"},{"key":"2026083102570599297_j_mr-2025-0086_ref_082","doi-asserted-by":"crossref","unstructured":"Richeldi, L, Azuma, A, Cottin, V, Hesslinger, C, Stowasser, S, Valenzuela, C, et al.. Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis. N\u00a0Engl J Med 2022;386:2178\u201387. https:\/\/doi.org\/10.1056\/nejmoa2201737.","DOI":"10.1056\/NEJMoa2201737"},{"key":"2026083102570599297_j_mr-2025-0086_ref_083","doi-asserted-by":"crossref","unstructured":"Liu, Y, Liu, Z, Li, X, Li, W, Yang, Z, Jiao, R, et al.. Nerandomilast improves bleomycin-induced systemic sclerosis-associated interstitial lung disease in mice by regulating the TGF-\u03b21 pathway. Inflammation 2024;48:1760\u201374. https:\/\/doi.org\/10.1007\/s10753-024-02153-9.","DOI":"10.1007\/s10753-024-02153-9"},{"key":"2026083102570599297_j_mr-2025-0086_ref_084","doi-asserted-by":"crossref","unstructured":"Reininger, D, Wolf, F, Mayr, CH, Wespel, SL, Laufhaeger, N, Geillinger-K\u00e4stle, K, et al.. Insights into the cellular and molecular mechanisms behind the antifibrotic effects of nerandomilast. Am J Respir Cell Mol Biol 2025;73:700\u201312. https:\/\/doi.org\/10.1165\/rcmb.2024-0614oc.","DOI":"10.1165\/rcmb.2024-0614OC"},{"key":"2026083102570599297_j_mr-2025-0086_ref_085","doi-asserted-by":"crossref","unstructured":"Reininger, D, Fundel\u2010Clemens, K, Mayr, CH, Wollin, L, Laemmle, B, Quast, K, et al.. PDE4B inhibition by nerandomilast: effects on lung fibrosis and transcriptome in fibrotic rats and on biomarkers in human lung epithelial cells. Br J Pharmacol 2024;181:4766\u201381. https:\/\/doi.org\/10.1111\/bph.17303.","DOI":"10.1111\/bph.17303"},{"key":"2026083102570599297_j_mr-2025-0086_ref_086","unstructured":"Boehringer Ingelheim (2022) FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis. 2024;"},{"key":"2026083102570599297_j_mr-2025-0086_ref_087","doi-asserted-by":"crossref","unstructured":"Maher, TM, Assassi, S, Azuma, A, Cottin, V, Hoffmann-Vold, AM, Kreuter, M, et al.. Nerandomilast in patients with progressive pulmonary fibrosis. N\u00a0Engl J Med 2025;392:2203\u201314. https:\/\/doi.org\/10.1056\/nejmoa2503643.","DOI":"10.1056\/NEJMoa2503643"},{"key":"2026083102570599297_j_mr-2025-0086_ref_088","doi-asserted-by":"crossref","unstructured":"Richeldi, L, Azuma, A, Cottin, V, Kreuter, M, Maher, TM, Martinez, FJ, et al.. Nerandomilast in patients with idiopathic pulmonary fibrosis. N\u00a0Engl J Med 2025;392:2193\u2013202. https:\/\/doi.org\/10.1056\/nejmoa2414108.","DOI":"10.1056\/NEJMoa2414108"},{"key":"2026083102570599297_j_mr-2025-0086_ref_089","doi-asserted-by":"crossref","unstructured":"Castelino, FV, Adegunsoye, A. Potential of phosphodiesterase 4B inhibitors in the treatment of interstitial lung disease associated with autoimmune diseases. Clin Exp Rheumatol 2024;43:119\u201325. https:\/\/doi.org\/10.55563\/clinexprheumatol\/yg6rck.","DOI":"10.55563\/clinexprheumatol\/yg6rck"},{"key":"2026083102570599297_j_mr-2025-0086_ref_090","doi-asserted-by":"crossref","unstructured":"Travis, WD, Hunninghake, G, King, TE, Lynch, DA, Colby, TV, Galvin, JR, et al.. Idiopathic nonspecific interstitial pneumonia: report of an American thoracic society project. Am J Respir Crit Care Med 2008;177:1338\u201347. https:\/\/doi.org\/10.1164\/rccm.200611-1685oc.","DOI":"10.1164\/rccm.200611-1685OC"},{"key":"2026083102570599297_j_mr-2025-0086_ref_091","doi-asserted-by":"crossref","unstructured":"Raghu, G, Remy-Jardin, M, Myers, JL, Richeldi, L, Ryerson, CJ, Lederer, DJ, et al.. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018;198:e44\u201368. https:\/\/doi.org\/10.1164\/rccm.201807-1255st.","DOI":"10.1164\/rccm.201807-1255ST"},{"key":"2026083102570599297_j_mr-2025-0086_ref_092","doi-asserted-by":"crossref","unstructured":"Mathai, SC, Danoff, SK. Management of interstitial lung disease associated with connective tissue disease. BMJ 2016;352:h6819. https:\/\/doi.org\/10.1136\/bmj.h6819.","DOI":"10.1136\/bmj.h6819"},{"key":"2026083102570599297_j_mr-2025-0086_ref_093","doi-asserted-by":"crossref","unstructured":"Yang, HW, Lee, SA, Shin, JM, Park, IH, Lee, HM. Glucocorticoids ameliorate TGF-\u03b21-mediated epithelial-to-mesenchymal transition of airway epithelium through MAPK and snail\/slug signaling pathways. Sci Rep 2017;7:3486. https:\/\/doi.org\/10.1038\/s41598-017-02358-z.","DOI":"10.1038\/s41598-017-02358-z"},{"key":"2026083102570599297_j_mr-2025-0086_ref_094","doi-asserted-by":"crossref","unstructured":"Wen, FQ, Kohyama, T, Sk\u00f6ld, CM, Zhu, YK, Liu, X, Romberger, DJ, et al.. Glucocorticoids modulate TGF-\u03b2 production by human fetal lung fibroblasts. Inflammation 2003;27:9\u201319. https:\/\/doi.org\/10.1023\/a:1022683010976.","DOI":"10.1023\/A:1022683010976"},{"key":"2026083102570599297_j_mr-2025-0086_ref_095","doi-asserted-by":"crossref","unstructured":"The Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N\u00a0-acetylcysteine for pulmonary fibrosis. N\u00a0Engl J Med 2012;366:1968\u201377. https:\/\/doi.org\/10.1056\/nejmoa1113354.","DOI":"10.1056\/NEJMoa1113354"},{"key":"2026083102570599297_j_mr-2025-0086_ref_096","doi-asserted-by":"crossref","unstructured":"Tashkin, DP, Elashoff, R, Clements, PJ, Goldin, J, Roth, MD, Furst, DE, et al.. Cyclophosphamide versus placebo in scleroderma lung disease. N\u00a0Engl J Med 2006;354:2655\u201366. https:\/\/doi.org\/10.1056\/nejmoa055120.","DOI":"10.1056\/NEJMoa055120"},{"key":"2026083102570599297_j_mr-2025-0086_ref_097","doi-asserted-by":"crossref","unstructured":"Tashkin, DP, Roth, MD, Clements, PJ, Furst, DE, Khanna, D, Kleerup, EC, et al.. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016;4:708\u201319. https:\/\/doi.org\/10.1016\/s2213-2600(16)30152-7.","DOI":"10.1016\/S2213-2600(16)30152-7"},{"key":"2026083102570599297_j_mr-2025-0086_ref_098","doi-asserted-by":"crossref","unstructured":"Khanna, D, Lin, CJF, Furst, DE, Goldin, J, Kim, G, Kuwana, M, et al.. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2020;8:963\u201374. https:\/\/doi.org\/10.1016\/s2213-2600(20)30318-0.","DOI":"10.1016\/S2213-2600(20)30318-0"},{"key":"2026083102570599297_j_mr-2025-0086_ref_099","doi-asserted-by":"crossref","unstructured":"Roofeh, D, Lin, CJF, Goldin, J, Kim, GH, Furst, DE, Denton, CP, et al.. Tocilizumab prevents progression of early systemic sclerosis\u2013associated interstitial lung disease. Arthritis Rheumatol 2021;73:1301\u201310. https:\/\/doi.org\/10.1002\/art.41668.","DOI":"10.1002\/art.41668"},{"key":"2026083102570599297_j_mr-2025-0086_ref_100","doi-asserted-by":"crossref","unstructured":"Flaherty, KR, Fell, CD, Huggins, JT, Nunes, H, Sussman, R, Valenzuela, C, et al.. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. Eur Respir J 2018;52:1800230. https:\/\/doi.org\/10.1183\/13993003.00230-2018.","DOI":"10.1183\/13993003.00230-2018"},{"key":"2026083102570599297_j_mr-2025-0086_ref_101","doi-asserted-by":"crossref","unstructured":"Vancheri, C, Kreuter, M, Richeldi, L, Ryerson, CJ, Valeyre, D, Grutters, JC, et al.. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. Results of the INJOURNEY trial. Am J Respir Crit Care Med 2018;197:356\u201363. https:\/\/doi.org\/10.1164\/rccm.201706-1301oc.","DOI":"10.1164\/rccm.201706-1301OC"},{"key":"2026083102570599297_j_mr-2025-0086_ref_102","doi-asserted-by":"crossref","unstructured":"Cottin, V, Richeldi, L, Rosas, I, Otaola, M, Song, JW, Tomassetti, S, et al.. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respir Res 2021;22:84. https:\/\/doi.org\/10.1186\/s12931-021-01668-1.","DOI":"10.1186\/s12931-021-01668-1"},{"key":"2026083102570599297_j_mr-2025-0086_ref_103","doi-asserted-by":"crossref","unstructured":"Distler, O, Highland, KB, Gahlemann, M, Azuma, A, Fischer, A, Mayes, MD, et al.. Nintedanib for systemic sclerosis\u2013associated interstitial lung disease. N\u00a0Engl J Med 2019;380:2518\u201328. https:\/\/doi.org\/10.1056\/nejmoa1903076.","DOI":"10.1056\/NEJMoa1903076"},{"key":"2026083102570599297_j_mr-2025-0086_ref_104","doi-asserted-by":"crossref","unstructured":"Wells, AU, Flaherty, KR, Brown, KK, Inoue, Y, Devaraj, A, Richeldi, L, et al.. Nintedanib in patients with progressive fibrosing interstitial lung diseases\u2014subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020;8:453\u201360. https:\/\/doi.org\/10.1016\/s2213-2600(20)30036-9.","DOI":"10.1016\/S2213-2600(20)30036-9"},{"key":"2026083102570599297_j_mr-2025-0086_ref_105","doi-asserted-by":"crossref","unstructured":"Raghu, G, Richeldi, L, Fern\u00e1ndez P\u00e9rez, ER, De Salvo, MC, Silva, RS, Song, JW, et al.. Pamrevlumab for idiopathic pulmonary fibrosis: the ZEPHYRUS-1 randomized clinical trial. JAMA 2024;332:380. https:\/\/doi.org\/10.1001\/jama.2024.8693.","DOI":"10.1164\/ajrccm-conference.2024.209.1_MeetingAbstracts.A6613"},{"key":"2026083102570599297_j_mr-2025-0086_ref_106","doi-asserted-by":"crossref","unstructured":"Corte, TJ, Behr, J, Cottin, V, Glassberg, MK, Kreuter, M, Martinez, FJ, et al.. Efficacy and safety of admilparant, an LPA-1 antagonist, in pulmonary fibrosis: a phase 2 randomized clinical trial. Am J Respir Crit Care Med 2025;211:230\u20138. https:\/\/doi.org\/10.1164\/rccm.202405-0977oc.","DOI":"10.1164\/rccm.202405-0977OC"},{"key":"2026083102570599297_j_mr-2025-0086_ref_107","doi-asserted-by":"crossref","unstructured":"Reynolds, CJ, Del Greco, MF, Allen, RJ, Flores, C, Jenkins, RG, Maher, TM, et al.. The causal relationship between gastro-oesophageal reflux disease and idiopathic pulmonary fibrosis: a bidirectional two-sample mendelian randomisation study. Eur Respir J 2023;61:2201585. https:\/\/doi.org\/10.1183\/13993003.01585-2022.","DOI":"10.1183\/13993003.01585-2022"},{"key":"2026083102570599297_j_mr-2025-0086_ref_108","doi-asserted-by":"crossref","unstructured":"Chen, P, Xie, L, Ma, L, Zhao, X, Chen, Y, Ge, Z. Prediction and analysis of genetic effect in idiopathic pulmonary fibrosis and gastroesophageal reflux disease. IET Syst Biol 2023;17:352\u201365. https:\/\/doi.org\/10.1049\/syb2.12081.","DOI":"10.1049\/syb2.12081"},{"key":"2026083102570599297_j_mr-2025-0086_ref_109","doi-asserted-by":"crossref","unstructured":"Targownik, LE, Fisher, DA, Saini, SD. AGA clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology 2022;162:1334\u201342. https:\/\/doi.org\/10.1053\/j.gastro.2021.12.247.","DOI":"10.1053\/j.gastro.2021.12.247"},{"key":"2026083102570599297_j_mr-2025-0086_ref_110","doi-asserted-by":"crossref","unstructured":"Noth, I, Wijsenbeek, M, Kolb, M, Bonella, F, Moros, L, Wachtlin, D, et al.. Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials. Eur Respir J 2019;54:1801797. https:\/\/doi.org\/10.1183\/13993003.01797-2018.","DOI":"10.1183\/13993003.01797-2018"},{"key":"2026083102570599297_j_mr-2025-0086_ref_111","doi-asserted-by":"crossref","unstructured":"Koteci, A, Morgan, AD, Portas, L, Whittaker, HR, Kallis, C, George, PM, et al.. Left-sided heart failure burden and mortality in idiopathic pulmonary fibrosis: a population-based study. BMC Pulm Med 2022;22:190. https:\/\/doi.org\/10.1186\/s12890-022-01973-5.","DOI":"10.1186\/s12890-022-01973-5"},{"key":"2026083102570599297_j_mr-2025-0086_ref_112","doi-asserted-by":"crossref","unstructured":"Gille, T, Didier, M, Boubaya, M, Moya, L, Sutton, A, Carton, Z, et al.. Obstructive sleep apnoea and related comorbidities in incident\u00a0idiopathic pulmonary fibrosis. Eur Respir J 2017;49:1601934. https:\/\/doi.org\/10.1183\/13993003.01934-2016.","DOI":"10.1183\/13993003.01934-2016"},{"key":"2026083102570599297_j_mr-2025-0086_ref_113","doi-asserted-by":"crossref","unstructured":"Hong, PY, Liu, D, Liu, A, Su, X, Zhang, XB, Zeng, YM. Causal associations of obstructive sleep apnea with chronic respiratory diseases: a mendelian randomization study. BMC Pulm Med 2024;24:409. https:\/\/doi.org\/10.1186\/s12890-024-03228-x.","DOI":"10.1186\/s12890-024-03228-x"},{"key":"2026083102570599297_j_mr-2025-0086_ref_114","doi-asserted-by":"crossref","unstructured":"Ora, J, Coppola, A, Perduno, A, Manzetti, GM, Puxeddu, E, Rogliani, P. Acute effect of oxygen therapy on exercise tolerance and dyspnea perception in ILD patients. Monaldi Arch Chest Dis 2021;92. https:\/\/doi.org\/10.4081\/monaldi.2021.1925.","DOI":"10.4081\/monaldi.2021.1925"},{"key":"2026083102570599297_j_mr-2025-0086_ref_115","doi-asserted-by":"crossref","unstructured":"Palm, A, Ekstr\u00f6m, M. Hypoxemia severity and survival in ILD and COPD on long-term oxygen therapy\u00a0\u2013\u00a0the population-based DISCOVERY study. Respir Med 2021;189:106659. https:\/\/doi.org\/10.1016\/j.rmed.2021.106659.","DOI":"10.1016\/j.rmed.2021.106659"},{"key":"2026083102570599297_j_mr-2025-0086_ref_116","doi-asserted-by":"crossref","unstructured":"Spruit, MA, Singh, SJ, Garvey, C, ZuWallack, R, Nici, L, Rochester, C, et al.. An official American thoracic society\/European respiratory society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013;188:e13\u201364. https:\/\/doi.org\/10.1164\/rccm.201309-1634st.","DOI":"10.1164\/rccm.201309-1634ST"},{"key":"2026083102570599297_j_mr-2025-0086_ref_117","doi-asserted-by":"crossref","unstructured":"Luu, B, Gupta, A, Fabiano, N, Wong, S, Fiedorowicz, JG, Fidler, L, et al.. Influence of pulmonary rehabilitation on symptoms of anxiety and depression in interstitial lung disease: a systematic review of randomized controlled trials. Respir Med 2023;219:107433. https:\/\/doi.org\/10.1016\/j.rmed.2023.107433.","DOI":"10.1016\/j.rmed.2023.107433"},{"key":"2026083102570599297_j_mr-2025-0086_ref_118","doi-asserted-by":"crossref","unstructured":"Salami, AC, Huddleston, SJ. Beating the odds: Long-term survival after lung transplantation. J\u00a0Thorac Dis 2023;15:4558\u201360. https:\/\/doi.org\/10.21037\/jtd-23-1018.","DOI":"10.21037\/jtd-23-1018"},{"key":"2026083102570599297_j_mr-2025-0086_ref_119","doi-asserted-by":"crossref","unstructured":"Arango Tom\u00e1s, EA, Algar Algar, FJ, Cerezo Madue\u00f1o, F, Salvatierra Vel\u00e1zquez, A. Evolution and risk factors for early mortality after lung transplantation for idiopathic pulmonary fibrosis: an experience of 20\u00a0years. Transplant Proc 2015;47:2656\u20138. https:\/\/doi.org\/10.1016\/j.transproceed.2015.09.048.","DOI":"10.1016\/j.transproceed.2015.09.048"},{"key":"2026083102570599297_j_mr-2025-0086_ref_120","doi-asserted-by":"crossref","unstructured":"Chambers, DC, Zuckermann, A, Cherikh, WS, Harhay, MO, Hayes, D, Hsich, E, et al.. The international thoracic organ transplant registry of the international society for heart and lung transplantation: 37th adult lung transplantation report \u2014\u00a02020; focus on deceased donor characteristics. J\u00a0Heart Lung Transplant 2020;39:1016\u201327. https:\/\/doi.org\/10.1016\/j.healun.2020.07.009.","DOI":"10.1016\/j.healun.2020.07.009"},{"key":"2026083102570599297_j_mr-2025-0086_ref_121","doi-asserted-by":"crossref","unstructured":"Funke, M, Zhao, Z, Xu, Y, Chun, J, Tager, AM. The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury. Am J Respir Cell Mol Biol 2012;46:355\u201364. https:\/\/doi.org\/10.1165\/rcmb.2010-0155oc.","DOI":"10.1165\/rcmb.2010-0155OC"},{"key":"2026083102570599297_j_mr-2025-0086_ref_122","doi-asserted-by":"crossref","unstructured":"Neighbors, M, Li, Q, Zhu, SJ, Liu, J, Wong, WR, Jia, G, et al.. Bioactive lipid lysophosphatidic acid species are associated with disease progression in idiopathic pulmonary fibrosis. J\u00a0Lipid Res 2023;64:100375. https:\/\/doi.org\/10.1016\/j.jlr.2023.100375.","DOI":"10.1016\/j.jlr.2023.100375"},{"key":"2026083102570599297_j_mr-2025-0086_ref_123","doi-asserted-by":"crossref","unstructured":"Tager, AM, LaCamera, P, Shea, BS, Campanella, GS, Selman, M, Zhao, Z, et al.. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008;14:45\u201354. https:\/\/doi.org\/10.1038\/nm1685.","DOI":"10.1038\/nm1685"},{"key":"2026083102570599297_j_mr-2025-0086_ref_124","doi-asserted-by":"crossref","unstructured":"Decato, BE, Leeming, DJ, Sand, JMB, Fischer, A, Du, S, Palmer, SM, et al.. LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in\u00a0vitro and in patients with idiopathic pulmonary fibrosis. Respir Res 2022;23:61. https:\/\/doi.org\/10.1186\/s12931-022-01980-4.","DOI":"10.1186\/s12931-022-01980-4"},{"key":"2026083102570599297_j_mr-2025-0086_ref_125","doi-asserted-by":"crossref","unstructured":"Corte, TJ, Lancaster, L, Swigris, JJ, Maher, TM, Goldin, JG, Palmer, SM, et al.. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Resp Res 2021;8:e001026. https:\/\/doi.org\/10.1136\/bmjresp-2021-001026.","DOI":"10.1136\/bmjresp-2021-001026"},{"key":"2026083102570599297_j_mr-2025-0086_ref_126","doi-asserted-by":"crossref","unstructured":"Henderson, NC, Arnold, TD, Katamura, Y, Giacomini, MM, Rodriguez, JD, McCarty, JH, et al.. Targeting of \u03b1v integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med 2013;19:1617\u201324. https:\/\/doi.org\/10.1038\/nm.3282.","DOI":"10.1038\/nm.3282"},{"key":"2026083102570599297_j_mr-2025-0086_ref_127","doi-asserted-by":"crossref","unstructured":"Leask, A, Hutchenreuther, J. Activation of latent TGF\u03b2 by \u03b1v\u03b21 integrin: of potential importance in myofibroblast activation in fibrosis. J\u00a0Cell Commun Signaling 2014;8:171\u20132. https:\/\/doi.org\/10.1007\/s12079-014-0221-2.","DOI":"10.1007\/s12079-014-0221-2"},{"key":"2026083102570599297_j_mr-2025-0086_ref_128","doi-asserted-by":"crossref","unstructured":"Lancaster, L, Cottin, V, Ramaswamy, M, Wuyts, WA, Jenkins, RG, Scholand, MB, et al.. Bexotegrast in patients with idiopathic pulmonary fibrosis: the INTEGRIS-IPF clinical trial. Am J Respir Crit Care Med 2024;210:424\u201334. https:\/\/doi.org\/10.1164\/rccm.202403-0636oc.","DOI":"10.1164\/rccm.202403-0636OC"},{"key":"2026083102570599297_j_mr-2025-0086_ref_129","doi-asserted-by":"crossref","unstructured":"Montesi, SB, Cosgrove, GP, Turner, SM, Zhou, IY, Efthimiou, N, Susnjar, A, et al.. Dual \u03b1v\u03b26 and \u03b1v\u03b21 inhibition over 12\u00a0weeks reduces active type I collagen deposition in individuals with idiopathic pulmonary fibrosis: a phase 2, double-blind, placebo-controlled clinical trial. Am J Respir Crit Care Med 2025;211:1229\u201340. https:\/\/doi.org\/10.1164\/rccm.202410-1934oc.","DOI":"10.1164\/rccm.202410-1934OC"},{"key":"2026083102570599297_j_mr-2025-0086_ref_130","doi-asserted-by":"crossref","unstructured":"Sharif, H, Wang, L, Wang, WL, Magupalli, VG, Andreeva, L, Qiao, Q, et al.. Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome. Nature 2019;570:338\u201343. https:\/\/doi.org\/10.1038\/s41586-019-1295-z.","DOI":"10.1038\/s41586-019-1295-z"},{"key":"2026083102570599297_j_mr-2025-0086_ref_131","doi-asserted-by":"crossref","unstructured":"Shi, J, Zhao, Y, Wang, K, Shi, X, Wang, Y, Huang, H, et al.. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 2015;526:660\u20135. https:\/\/doi.org\/10.1038\/nature15514.","DOI":"10.1038\/nature15514"},{"key":"2026083102570599297_j_mr-2025-0086_ref_132","doi-asserted-by":"crossref","unstructured":"Nguyen, TH, Nguyen, HHN, Nguyen, TD, Tran, VTH, Nguyen, HA, Pham, DV. NLRP3 inflammasome activation contributes to the development of the pro-fibrotic phenotype of lung fibroblasts. Biochem Pharmacol 2024;229:116496. https:\/\/doi.org\/10.1016\/j.bcp.2024.116496.","DOI":"10.1016\/j.bcp.2024.116496"},{"key":"2026083102570599297_j_mr-2025-0086_ref_133","doi-asserted-by":"crossref","unstructured":"Abdelhady, R, Cavalu, S, Saber, S, Elmowafy, R, Morsy, NE, Ibrahim, S, et al.. Mirtazapine, an atypical antidepressant, mitigates lung fibrosis by suppressing NLPR3 inflammasome and fibrosis-related mediators in endotracheal bleomycin rat model. Biomed Pharmacother 2023;161:114553. https:\/\/doi.org\/10.1016\/j.biopha.2023.114553.","DOI":"10.1016\/j.biopha.2023.114553"},{"key":"2026083102570599297_j_mr-2025-0086_ref_134","doi-asserted-by":"crossref","unstructured":"Parmar, DV, Kansagra, KA, Momin, T, Patel, HB, Jansari, GA, Bhavsar, J, et al.. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral NLRP3 inflammasome inhibitor ZYIL1: first\u2010in\u2010human phase 1 studies (single ascending dose and multiple ascending dose). Clin Pharm Drug Dev 2023;12:202\u201311. https:\/\/doi.org\/10.1002\/cpdd.1162.","DOI":"10.1002\/cpdd.1162"},{"key":"2026083102570599297_j_mr-2025-0086_ref_135","doi-asserted-by":"crossref","unstructured":"Gatlik, E, Mehes, B, Voltz, E, Sommer, U, Tritto, E, Lestini, G, et al.. First\u2010in\u2010human safety, tolerability, and pharmacokinetic results of DFV890, an oral low\u2010molecular\u2010weight NLRP3 inhibitor. Clin Transl Sci 2024;17:e13789. https:\/\/doi.org\/10.1111\/cts.13789.","DOI":"10.1111\/cts.13789"},{"key":"2026083102570599297_j_mr-2025-0086_ref_136","doi-asserted-by":"crossref","unstructured":"Wolffs, K, Li, R, Mansfield, B, Pass, DA, Bruce, RT, Huang, P, et al.. Calcium-sensing receptor as a novel target for the treatment of idiopathic pulmonary fibrosis. Biomolecules 2025;15:509. https:\/\/doi.org\/10.3390\/biom15040509.","DOI":"10.3390\/biom15040509"},{"key":"2026083102570599297_j_mr-2025-0086_ref_137","doi-asserted-by":"crossref","unstructured":"Diao, J, DeBono, A, Josephs, TM, Bourke, JE, Capuano, B, Gregory, KJ, et al.. Therapeutic opportunities of targeting allosteric binding sites on the calcium-sensing receptor. ACS Pharmacol Transl Sci 2021;4:666\u201379. https:\/\/doi.org\/10.1021\/acsptsci.1c00046.","DOI":"10.1021\/acsptsci.1c00046"},{"key":"2026083102570599297_j_mr-2025-0086_ref_138","doi-asserted-by":"crossref","unstructured":"Yan, P, Liu, J, Li, Z, Wang, J, Zhu, Z, Wang, L, et al.. Glycolysis reprogramming in idiopathic pulmonary fibrosis: unveiling the mystery of lactate in the lung. Int J Mol Sci 2023;25:315. https:\/\/doi.org\/10.3390\/ijms25010315.","DOI":"10.3390\/ijms25010315"},{"key":"2026083102570599297_j_mr-2025-0086_ref_139","doi-asserted-by":"crossref","unstructured":"Sontake, V, Wang, Y, Kasam, RK, Sinner, D, Reddy, GB, Naren, AP, et al.. Hsp90 regulation of fibroblast activation in pulmonary fibrosis. JCI Insight 2017;2:e91454. https:\/\/doi.org\/10.1172\/jci.insight.91454.","DOI":"10.1172\/jci.insight.91454"},{"key":"2026083102570599297_j_mr-2025-0086_ref_140","doi-asserted-by":"crossref","unstructured":"Li, X, Yu, H, Liang, L, Bi, Z, Wang, Y, Gao, S, et al.. Myricetin ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-\u03b2 signaling via targeting HSP90\u03b2. Biochem Pharmacol 2020;178:114097. https:\/\/doi.org\/10.1016\/j.bcp.2020.114097.","DOI":"10.1016\/j.bcp.2020.114097"},{"key":"2026083102570599297_j_mr-2025-0086_ref_141","doi-asserted-by":"crossref","unstructured":"Sibinska, Z, Tian, X, Korfei, M, Kojonazarov, B, Kolb, JS, Klepetko, W, et al.. Amplified canonical transforming growth factor-\u03b2 signalling via heat shock protein 90 in pulmonary fibrosis. Eur Respir J 2017;49:1501941. https:\/\/doi.org\/10.1183\/13993003.01941-2015.","DOI":"10.1183\/13993003.01941-2015"},{"key":"2026083102570599297_j_mr-2025-0086_ref_142","doi-asserted-by":"crossref","unstructured":"Solopov, P, Colunga Biancatelli, RML, Marinova, M, Dimitropoulou, C, Catravas, JD. The HSP90 inhibitor, AUY-922, ameliorates the development of nitrogen mustard-induced pulmonary fibrosis and lung dysfunction in mice. IJMS 2020;21:4740. https:\/\/doi.org\/10.3390\/ijms21134740.","DOI":"10.3390\/ijms21134740"},{"key":"2026083102570599297_j_mr-2025-0086_ref_143","doi-asserted-by":"crossref","unstructured":"Pun, FW, Ozerov, IV, Zhavoronkov, A. AI-powered therapeutic target discovery. Trends Pharmacol Sci 2023;44:561\u201372. https:\/\/doi.org\/10.1016\/j.tips.2023.06.010.","DOI":"10.1016\/j.tips.2023.06.010"},{"key":"2026083102570599297_j_mr-2025-0086_ref_144","doi-asserted-by":"crossref","unstructured":"Ren, F, Aliper, A, Chen, J, Zhao, H, Rao, S, Kuppe, C, et al.. A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nat Biotechnol 2025;43:63\u201375. https:\/\/doi.org\/10.1038\/s41587-024-02143-0.","DOI":"10.1038\/s41587-024-02143-0"},{"key":"2026083102570599297_j_mr-2025-0086_ref_145","doi-asserted-by":"crossref","unstructured":"Xu, Z, Ren, F, Wang, P, Cao, J, Tan, C, Ma, D, et al.. A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nat Med 2025;31:2602\u201310. https:\/\/doi.org\/10.1038\/s41591-025-03743-2.","DOI":"10.1038\/s41591-025-03743-2"},{"key":"2026083102570599297_j_mr-2025-0086_ref_146","doi-asserted-by":"crossref","unstructured":"Han, S, Lee, JE, Kang, S, So, M, Jin, H, Lee, JH, et al.. Standigm ASKTM: knowledge graph and artificial intelligence platform applied to target discovery in idiopathic pulmonary fibrosis. Briefings Bioinf 2024;25:bbae035. https:\/\/doi.org\/10.1093\/bib\/bbae035.","DOI":"10.1093\/bib\/bbae035"},{"key":"2026083102570599297_j_mr-2025-0086_ref_147","doi-asserted-by":"crossref","unstructured":"Lee, JY, Reyes, NS, Ravishankar, S, Zhou, M, Krasilnikov, M, Ringler, C, et al.. An in\u00a0vivo screening platform identifies senolytic compounds that target p16INK4a+ fibroblasts in lung fibrosis. J\u00a0Clin Investig 2024;134:e173371. https:\/\/doi.org\/10.1172\/jci173371.","DOI":"10.1172\/JCI173371"},{"key":"2026083102570599297_j_mr-2025-0086_ref_148","doi-asserted-by":"crossref","unstructured":"Nan, Y, Federico, FN, Humphries, S, Mackintosh, JA, Grainge, C, Jo, HE, et al.. Prognostication in patients with idiopathic pulmonary fibrosis using quantitative airway analysis from HRCT: a retrospective study. Eur Respir J 2025;66:2500981. https:\/\/doi.org\/10.1183\/13993003.00981-2025.","DOI":"10.1183\/13993003.00981-2025"},{"key":"2026083102570599297_j_mr-2025-0086_ref_149","doi-asserted-by":"crossref","unstructured":"Zhang, T, Lee, JH, Kim, SR, Chung, JH, Jin, GY. What role does artificial intelligence-driven quantitative analysis of chest computed tomography play in providing pulmonary function for idiopathic pulmonary fibrosis patients undergoing pirfenidone treatment? Quant Imaging Med Surg 2025;15:6604\u201315. https:\/\/doi.org\/10.21037\/qims-2025-380.","DOI":"10.21037\/qims-2025-380"},{"key":"2026083102570599297_j_mr-2025-0086_ref_150","doi-asserted-by":"crossref","unstructured":"Furukawa, T, Oyama, S, Yokota, H, Kondoh, Y, Kataoka, K, Johkoh, T, et al.. A comprehensible machine learning tool to differentially diagnose idiopathic pulmonary fibrosis from other chronic interstitial lung diseases. Respirology 2022;27:739\u201346. https:\/\/doi.org\/10.1111\/resp.14310.","DOI":"10.1111\/resp.14310"},{"key":"2026083102570599297_j_mr-2025-0086_ref_151","doi-asserted-by":"crossref","unstructured":"Wu, X, Yin, C, Chen, X, Zhang, Y, Su, Y, Shi, J, et al.. Idiopathic pulmonary fibrosis mortality risk prediction based on artificial intelligence: the CTPF model. Front Pharmacol 2022;13:878764. https:\/\/doi.org\/10.3389\/fphar.2022.878764.","DOI":"10.3389\/fphar.2022.878764"},{"key":"2026083102570599297_j_mr-2025-0086_ref_152","doi-asserted-by":"crossref","unstructured":"Tomoto, M, Mineharu, Y, Sato, N, Tamada, Y, Nogami-Itoh, M, Kuroda, M, et al.. Idiopathic pulmonary fibrosis-specific Bayesian network integrating extracellular vesicle proteome and clinical information. Sci Rep 2024;14:1315. https:\/\/doi.org\/10.1038\/s41598-023-50905-8.","DOI":"10.1038\/s41598-023-50905-8"},{"key":"2026083102570599297_j_mr-2025-0086_ref_153","doi-asserted-by":"crossref","unstructured":"Aliper, A, Kudrin, R, Polykovskiy, D, Kamya, P, Tutubalina, E, Chen, S, et al.. Prediction of clinical trials outcomes based on target choice and clinical trial design with multi-modal artificial intelligence. Clin Pharmacol Ther 2023;114:972\u201380. https:\/\/doi.org\/10.1002\/cpt.3008.","DOI":"10.1002\/cpt.3008"},{"key":"2026083102570599297_j_mr-2025-0086_ref_154","doi-asserted-by":"crossref","unstructured":"Ramspek, CL, Jager, KJ, Dekker, FW, Zoccali, C, van Diepen, M. External validation of prognostic models: what, why, how, when and where? Clin Kidney J 2021;14:49\u201358. https:\/\/doi.org\/10.1093\/ckj\/sfaa188.","DOI":"10.1093\/ckj\/sfaa188"},{"key":"2026083102570599297_j_mr-2025-0086_ref_155","doi-asserted-by":"crossref","unstructured":"Bender, A, Cort\u00e9s-Ciriano, I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: ways to make an impact, and why we are not there yet. Drug Discov Today 2021;26:511\u201324. https:\/\/doi.org\/10.1016\/j.drudis.2020.12.009.","DOI":"10.1016\/j.drudis.2020.12.009"},{"key":"2026083102570599297_j_mr-2025-0086_ref_156","doi-asserted-by":"crossref","unstructured":"Maher, TM, Ford, P, Brown, KK, Costabel, U, Cottin, V, Danoff, SK, et al.. Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials. JAMA 2023;329:1567. https:\/\/doi.org\/10.1001\/jama.2023.5355.","DOI":"10.1001\/jama.2023.5355"},{"key":"2026083102570599297_j_mr-2025-0086_ref_157","doi-asserted-by":"crossref","unstructured":"Raghu, G, Van Den Blink, B, Hamblin, MJ, Brown, AW, Golden, JA, Ho, LA, et al.. Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial. JAMA 2018;319:2299. https:\/\/doi.org\/10.1001\/jama.2018.6129.","DOI":"10.1001\/jama.2018.6129"},{"key":"2026083102570599297_j_mr-2025-0086_ref_158","doi-asserted-by":"crossref","unstructured":"Nambiar, A, Kellogg, D, Justice, J, Goros, M, Gelfond, J, Pascual, R, et al.. Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability. EBioMedicine 2023;90:104481. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104481.","DOI":"10.1016\/j.ebiom.2023.104481"},{"key":"2026083102570599297_j_mr-2025-0086_ref_159","doi-asserted-by":"crossref","unstructured":"Thannickal, VJ, Jandeleit\u2010Dahm, K, Szyndralewiez, C, T\u00f6r\u00f6k, NJ. Pre\u2010clinical evidence of a dual NADPH oxidase 1\/4 inhibitor (setanaxib) in liver, kidney and lung fibrosis. J\u00a0Cell Mol Med 2023;27:471\u201381. https:\/\/doi.org\/10.1111\/jcmm.17649.","DOI":"10.1111\/jcmm.17649"},{"key":"2026083102570599297_j_mr-2025-0086_ref_160","doi-asserted-by":"crossref","unstructured":"Song, Y, Ali, FN, Ye, Z, Zarzoso, J, Rogowski, J, Sun, Y, et al.. Pharmacokinetics of fipaxalparant, a small\u2010molecule selective negative allosteric modulator of lysophosphatidic acid receptor 1, and the effect of food in healthy volunteers. Clin Pharmacol Drug Dev 2024;13:819\u201327. https:\/\/doi.org\/10.1002\/cpdd.1417.","DOI":"10.1002\/cpdd.1417"},{"key":"2026083102570599297_j_mr-2025-0086_ref_161","unstructured":"Clinical trail NCT06440746: Efficacy and safety of olokizumab in patients with progressive fibrosing interstitial lung diseases [Internet]. National Library of Medicine, 2024. https:\/\/clinicaltrials.gov\/study\/NCT06440746."},{"key":"2026083102570599297_j_mr-2025-0086_ref_162","unstructured":"Clinical trail NCT05828953:Anlotinib capsules in the treatment for IPF\/PF-ILDs [Internet]. National Library of Medicine, 2021. https:\/\/clinicaltrials.gov\/study\/NCT05828953."},{"key":"2026083102570599297_j_mr-2025-0086_ref_163","doi-asserted-by":"crossref","unstructured":"Maher, TM, Goldin, JG, Hood, J, Pitman, J, de Los Rios, M, Hobbs, BP, et al.. Taladegib for the treatment of Idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial. Lancet Respir Med 2025;13:1001\u2013101. https:\/\/doi.org\/10.1016\/S2213-2600(25)00239-5.","DOI":"10.1016\/S2213-2600(25)00239-5"},{"key":"2026083102570599297_j_mr-2025-0086_ref_164","doi-asserted-by":"crossref","unstructured":"Richeldi, L, Schiffman, C, Behr, J, Inoue, Y, Corte, TJ, Cottin, V, et al.. Zinpentraxin alfa for idiopathic pulmonary fibrosis: the randomized phase III STARSCAPE trial. Am J Respir Crit Care Med 2024;209:1132\u201340. https:\/\/doi.org\/10.1164\/rccm.202401-0116oc.","DOI":"10.1164\/rccm.202401-0116OC"},{"key":"2026083102570599297_j_mr-2025-0086_ref_165","doi-asserted-by":"crossref","unstructured":"Kim, J, Hematti, P. Mesenchymal stem cell\u2013educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol 2009;37:1445\u201353. https:\/\/doi.org\/10.1016\/j.exphem.2009.09.004.","DOI":"10.1016\/j.exphem.2009.09.004"},{"key":"2026083102570599297_j_mr-2025-0086_ref_166","doi-asserted-by":"crossref","unstructured":"Ortiz, LA, Gambelli, F, McBride, C, Gaupp, D, Baddoo, M, Kaminski, N, et al.. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci 2003;100:8407\u201311. https:\/\/doi.org\/10.1073\/pnas.1432929100.","DOI":"10.1073\/pnas.1432929100"},{"key":"2026083102570599297_j_mr-2025-0086_ref_167","doi-asserted-by":"crossref","unstructured":"Glassberg, MK, Minkiewicz, J, Toonkel, RL, Simonet, ES, Rubio, GA, DiFede, D, et al.. Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER). Chest 2017;151:971\u201381. https:\/\/doi.org\/10.1016\/j.chest.2016.10.061.","DOI":"10.1016\/j.chest.2016.10.061"},{"key":"2026083102570599297_j_mr-2025-0086_ref_168","unstructured":"Clinical trail NCT06440746: Clinical trial of human umbilical cord mesenchymal stem cells (IxCell hUC-MSC-P) in the treatment of CTD-ILD [Internet]. National Library of Medicine, 2025, https:\/\/clinicaltrials.gov\/study\/NCT06823063."},{"key":"2026083102570599297_j_mr-2025-0086_ref_169","unstructured":"Clinical trail NCT06440746: REGEND001 autologous basal layer stem cell transplantation for interstitial lung disease (ILD): A Translational Application Study [Internet]. National Library of Medicine, 2025, https:\/\/clinicaltrials.gov\/study\/NCT06998706."},{"key":"2026083102570599297_j_mr-2025-0086_ref_170","doi-asserted-by":"crossref","unstructured":"Harrell, CR, Djonov, V, Volarevic, A, Arsenijevic, A, Volarevic, V. Molecular mechanisms responsible for the therapeutic potential of mesenchymal stem cell-derived exosomes in the treatment of lung fibrosis. Int J Mol Sci 2024;25:4378. https:\/\/doi.org\/10.3390\/ijms25084378.","DOI":"10.3390\/ijms25084378"},{"key":"2026083102570599297_j_mr-2025-0086_ref_171","doi-asserted-by":"crossref","unstructured":"Nija, RJ, Nithya, TG. Pulmonary fibrosis and exosomes: pathways to treatment. Mol Biol Rep 2025;52:749. https:\/\/doi.org\/10.1007\/s11033-025-10855-y.","DOI":"10.1007\/s11033-025-10855-y"},{"key":"2026083102570599297_j_mr-2025-0086_ref_172","doi-asserted-by":"crossref","unstructured":"Chen, Z, Yun, X, Tian, J, Li, F, Zhang, Z, Meng, J, et al.. Engineering macrophage-derived exosome to deliver pirfenidone: a novel approach to combat silicotic pulmonary fibrosis. Adv Healthcare Mater 2025;14:e2403227. https:\/\/doi.org\/10.1002\/adhm.202403227.","DOI":"10.1002\/adhm.202403227"},{"key":"2026083102570599297_j_mr-2025-0086_ref_173","doi-asserted-by":"crossref","unstructured":"Dinh, PUC, Paudel, D, Brochu, H, Popowski, KD, Gracieux, MC, Cores, J, et al.. Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis. Nat Commun 2020;11:1064. https:\/\/doi.org\/10.1038\/s41467-020-14344-7.","DOI":"10.1038\/s41467-020-14344-7"},{"key":"2026083102570599297_j_mr-2025-0086_ref_174","doi-asserted-by":"crossref","unstructured":"Li, M, Huang, H, Wei, X, Li, H, Li, J, Xie, B, et al.. Clinical investigation on nebulized human umbilical cord MSC-derived extracellular vesicles for pulmonary fibrosis treatment. Signal Transduction Targeted Ther 2025;10:179. https:\/\/doi.org\/10.1038\/s41392-025-02262-3.","DOI":"10.1038\/s41392-025-02262-3"},{"key":"2026083102570599297_j_mr-2025-0086_ref_175","doi-asserted-by":"crossref","unstructured":"Alnefaie, A, Albogami, S, Asiri, Y, Ahmad, T, Alotaibi, SS, Al-Sanea, MM, et al.. Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions. Front Bioeng Biotechnol 2022;10:797440. https:\/\/doi.org\/10.3389\/fbioe.2022.797440.","DOI":"10.3389\/fbioe.2022.797440"},{"key":"2026083102570599297_j_mr-2025-0086_ref_176","doi-asserted-by":"crossref","unstructured":"Aghajanian, H, Kimura, T, Rurik, JG, Hancock, AS, Leibowitz, MS, Li, L, et al.. Targeting cardiac fibrosis with engineered T\u00a0cells. Nature 2019;573:430\u20133. https:\/\/doi.org\/10.1038\/s41586-019-1546-z.","DOI":"10.1038\/s41586-019-1546-z"},{"key":"2026083102570599297_j_mr-2025-0086_ref_177","doi-asserted-by":"crossref","unstructured":"Basalova, N, Alexandrushkina, N, Grigorieva, O, Kulebyakina, M, Efimenko, A. Fibroblast activation protein alpha (FAP\u03b1) in fibrosis: beyond a perspective marker for activated stromal cells? Biomolecules 2023;13:1718. https:\/\/doi.org\/10.3390\/biom13121718.","DOI":"10.3390\/biom13121718"},{"key":"2026083102570599297_j_mr-2025-0086_ref_178","doi-asserted-by":"crossref","unstructured":"Xiao, BF, Zhang, JT, Zhu, YG, Cui, XR, Lu, ZM, Yu, BT, et al.. Chimeric antigen receptor T-cell therapy in lung cancer: potential and challenges. Front Immunol 2021;12:782775. https:\/\/doi.org\/10.3389\/fimmu.2021.782775.","DOI":"10.3389\/fimmu.2021.782775"},{"key":"2026083102570599297_j_mr-2025-0086_ref_179","doi-asserted-by":"crossref","unstructured":"Magnini, D, Montemurro, G, Iovene, B, Tagliaboschi, L, Gerardi, RE, Lo, GE, et al.. Idiopathic pulmonary fibrosis: molecular endotypes of fibrosis stratifying existing and emerging therapies. Respiration 2017;93:379\u201395. https:\/\/doi.org\/10.1159\/000475780.","DOI":"10.1159\/000475780"},{"key":"2026083102570599297_j_mr-2025-0086_ref_180","doi-asserted-by":"crossref","unstructured":"Kou, M, Jiao, Y, Li, Z, Wei, B, Li, Y, Cai, Y, et al.. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Eur J Clin Pharmacol 2024;80:1445\u201360. https:\/\/doi.org\/10.1007\/s00228-024-03720-7.","DOI":"10.1007\/s00228-024-03720-7"},{"key":"2026083102570599297_j_mr-2025-0086_ref_181","doi-asserted-by":"crossref","unstructured":"Yamauchi, H, Bando, M, Okuyama, A, Takasaki, T, Hisata, S, Nakayama, M, et al.. Digital clubbing predicts the efficacy of antifibrotic drugs in patients with idiopathic pulmonary fibrosis. Ann Palliat Med 2025;14:231\u20138. https:\/\/doi.org\/10.21037\/apm-24-177.","DOI":"10.21037\/apm-24-177"},{"key":"2026083102570599297_j_mr-2025-0086_ref_182","doi-asserted-by":"crossref","unstructured":"Veit, T, Barnikel, M, Crispin, A, Kneidinger, N, Ceelen, F, Arnold, P, et al.. Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study. Respir Res 2020;21:270. https:\/\/doi.org\/10.1186\/s12931-020-01524-8.","DOI":"10.1186\/s12931-020-01524-8"},{"key":"2026083102570599297_j_mr-2025-0086_ref_183","doi-asserted-by":"crossref","unstructured":"Liu, X, Qin, X, Qin, H, Jia, C, Yuan, Y, Sun, T, et al.. Characterization of the heterogeneity of endothelial cells in bleomycin-induced lung fibrosis using single-cell RNA sequencing. Angiogenesis 2021;24:809\u201321. https:\/\/doi.org\/10.1007\/s10456-021-09795-5.","DOI":"10.1007\/s10456-021-09795-5"},{"key":"2026083102570599297_j_mr-2025-0086_ref_184","doi-asserted-by":"crossref","unstructured":"Buschulte, K, Cottin, V, Wijsenbeek, M, Kreuter, M, Diesler, R. The world of rare interstitial lung diseases. Eur Respir Rev 2023;32:220161. https:\/\/doi.org\/10.1183\/16000617.0161-2022.","DOI":"10.1183\/16000617.0161-2022"},{"key":"2026083102570599297_j_mr-2025-0086_ref_185","doi-asserted-by":"crossref","unstructured":"Wang, X, Xia, X, Hou, Y, Zhang, H, Han, W, Sun, J, et al.. Diagnosis of early idiopathic pulmonary fibrosis: current status and future perspective. Respir Res 2025;26:192. https:\/\/doi.org\/10.1186\/s12931-025-03270-1.","DOI":"10.1186\/s12931-025-03270-1"}],"container-title":["Medical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/mr-2025-0086\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/mr-2025-0086\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:59:22Z","timestamp":1788145162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/mr-2025-0086\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":185,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,6,16]]},"published-print":{"date-parts":[[2026,8,24]]}},"alternative-id":["10.1515\/mr-2025-0086"],"URL":"https:\/\/doi.org\/10.1515\/mr-2025-0086","relation":{},"ISSN":["2749-9642"],"issn-type":[{"value":"2749-9642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]}}}